/MRK
MRK Stock - Merck & Co., Inc.
Healthcare|Drug Manufacturers - GeneralNYSE
$101.09+0.40%
+$0.40 (+0.40%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.90
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).80
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+15.0%upside
Target: $116.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MRK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$100.08 – $102.10
TARGET (TP)$116.29
STOP LOSS$93.00
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.30
52W High$105.84
52W Low$73.31
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $64.17B | $60.12B | $59.28B | $48.70B | $41.52B |
| Gross Profit | $48.98B | $43.99B | $41.87B | $35.08B | $27.90B |
| Gross Margin | 76.3% | 73.2% | 70.6% | 72.0% | 67.2% |
| Operating Income | $20.22B | $2.95B | $18.28B | $13.20B | $5.55B |
| Net Income | $17.12B | $365.00M | $14.52B | $13.05B | $7.07B |
| Net Margin | 26.7% | 0.6% | 24.5% | 26.8% | 17.0% |
| EPS | $6.76 | $0.14 | $5.73 | $5.16 | $2.79 |
Company Overview
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
17
59%
Hold / Neutral
11
38%
Sell / Underperform
1
3%
Analyst Consensus🟡 Mixed
17 Bullish12 Neutral/Bearish
Price Targets
$113
Average Target
↑ 12.0% Upside
Now
$84
Low
$113
Average
$135
High
Based on 29 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | BMO Capital Markets | Upgrade | Outperform | $130 |
| November 24th 2025 | Wells Fargo | Upgrade | Overweight | $125 |
| November 13th 2025 | Scotiabank | Initiation | Sector Outperform | $105 |
| October 13th 2025 | Citigroup | Resumed | Neutral | $95 |
| September 17th 2025 | Berenberg | Downgrade | Hold | $90 |
| May 14th 2025 | Citigroup | Downgrade | Neutral | $84 |
| April 22nd 2025 | Cantor Fitzgerald | Initiation | Neutral | $85 |
| February 18th 2025 | Deutsche Bank | Downgrade | Hold | $105← $128 |
| February 10th 2025 | TD Cowen | Downgrade | Hold | $100← $121 |
| January 8th 2025 | Truist | Downgrade | Hold | $110 |
| December 20th 2024 | BMO Capital Markets | Downgrade | Market Perform | $105← $136 |
| December 10th 2024 | BofA Securities | Resumed | Buy | $121 |
| December 4th 2024 | HSBC Securities | Upgrade | Buy | $130 |
| November 15th 2024 | Wolfe Research | Initiation | Peer Perform | - |
| November 11th 2024 | Daiwa Securities | Downgrade | Neutral | - |
Earnings History & Surprises
MRKBeat Rate
94%
Last 16 quarters
Avg Surprise
+15.3%
EPS vs Estimate
Beats / Misses
15/1
Last 12 quarters
Latest EPS
$2.58
Q4 2025
EPS Surprise History
Q1 24
+133.3%
$0.03vs$-0.09
Q2 24
+10.1%
$2.07vs$1.88
Q3 24
+6.0%
$2.28vs$2.15
Q4 24
+4.7%
$1.57vs$1.50
Q1 25
-7.0%
$1.72vs$1.85
Q2 25
+4.2%
$2.22vs$2.13
Q3 25
+4.9%
$2.13vs$2.03
Q4 25
+9.3%
$2.58vs$2.36
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2026 | Oct 29, 2026 | — | — | — | — |
Q3 2026 | Aug 4, 2026 | — | — | — | — |
Q2 2026 | Apr 30, 2026 | — | — | — | — |
Q1 2026 | Feb 3, 2026 | $2.08 | — | — | — |
Q4 2025 | Oct 30, 2025 | $2.36 | $2.58 | +9.3% | ✓ BEAT |
Q3 2025 | Jul 29, 2025 | $2.03 | $2.13 | +4.9% | ✓ BEAT |
Q2 2025 | Apr 24, 2025 | $2.13 | $2.22 | +4.2% | ✓ BEAT |
Q1 2025 | Feb 4, 2025 | $1.85 | $1.72 | -7.0% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $1.50 | $1.57 | +4.7% | ✓ BEAT |
Q3 2024 | Jul 30, 2024 | $2.15 | $2.28 | +6.0% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $1.88 | $2.07 | +10.1% | ✓ BEAT |
Q1 2024 | Feb 1, 2024 | $-0.09 | $0.03 | +133.3% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $1.95 | $2.13 | +9.2% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $-2.17 | $-2.06 | +5.1% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $1.32 | $1.40 | +6.1% | ✓ BEAT |
Q1 2023 | Feb 2, 2023 | $1.56 | $1.62 | +3.8% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $1.67 | $1.85 | +10.8% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $1.70 | $1.87 | +10.0% | ✓ BEAT |
Q2 2022 | Apr 28, 2022 | $1.83 | $2.14 | +16.9% | ✓ BEAT |
Q1 2022 | Feb 3, 2022 | $1.53 | $1.80 | +17.6% | ✓ BEAT |
Latest News
Shars of drug companies are higher after announcing deals with President Trump for lower drug prices.
📈 PositiveBenzinga•Dec 19, 2025, 08:34 PM•Also: , ,
Merck Reaches Historic Agreement With Trump Administration To Lower Drug Prices, Advance Enlicitide As Potential First Oral PCSK9 Inhibitor And Expand U.S. Investment
📈 PositiveBenzinga•Dec 19, 2025, 07:42 PM
President Trump Says The 3 Of The 17 Pharmaceutical Companies Who Have Not Agreed Are Coming In Next Week
➖ NeutralBenzinga•Dec 19, 2025, 07:30 PM•Also: , ,
Senior Administration Official Says President Trump To Announce Deals With Nine Pharmaceutical Companies To Reduce Drug Prices; Deals Are With Amgen, Bristol Myers Squibb, Roche's GenenTech, Gilead, GSK, Merck, Novartis, Sanofi And Boehringer Ingelheim; Each Manufacturer Agrees To Reduce Prices On Majority Of Medications Sold Through Medicaid; Companies Commit To $150B In New Investment In Manufacturing And R&D In U.S.
📈 PositiveBenzinga•Dec 19, 2025, 07:20 PM•Also: , ,
'Drug Companies Line Up To Make Deals With Trump After Initial Hesitation; At Least Seven Drug Companies Are Set To Announce Price Cuts With Trump At White House On Friday, Including GlaxoSmithKline, Merck And Sanofi' - Washington Post
📈 PositiveBenzinga•Dec 19, 2025, 05:40 PM•Also: ,
'Several top drugmakers to lower US prices for some drugs-sources' - Reuters
📈 PositiveBenzinga•Dec 19, 2025, 12:42 PM•Also: , ,
Pyxis plummets following phase 1 data on candidate for head and neck cancer
📉 NegativeSeeking Alpha•Dec 18, 2025, 04:53 PM•Also:
BMO Capital Upgrades Merck & Co to Outperform, Raises Price Target to $130
📈 PositiveBenzinga•Dec 18, 2025, 12:49 PM
'U.S. FDA Moving To Fast-Track Reviews Of Two Merck Drugs Under Commissioner National Priority Voucher Pilot Program; Merck's Cholesterol Pill Enlicitide And Cancer Therapy Sac-TMT Tapped For Program; FDA Expects Respective April And October/ November Submission Dates For Enlicitide And Sac-TMT, Internal Documents Say' - Reuters Exclusive
📈 PositiveBenzinga•Dec 17, 2025, 08:36 PM
Merck's Topline Results From Phase 3 KEYNOTE-b15 Trial Showed Keytruda (Pembrolizumab) Plus Padcev, As Before And After Surgery, Demonstrated Meaningful Improvement In Event-free Survival, Overall Survival, And Pathologic Complete Response Rates Versus Neoadjuvant Chemotherapy And Surgery In Patients With Muscle-invasive Bladder Cancer
📈 PositiveBenzinga•Dec 17, 2025, 11:49 AM
The FDA Has Designated Adagene's Muzastotug, In Combination With Merck's Keytruda (Pembrolizumab), As A Fast Track Product For Adult Patients With Microsatellite Stable Metastatic Colorectal Cancer Without Current Or Active Liver Metastases
📈 PositiveBenzinga•Dec 16, 2025, 12:06 PM•Also:
B of A Securities Maintains Buy on Merck & Co, Raises Price Target to $120
📈 PositiveBenzinga•Dec 15, 2025, 01:20 PM
Morgan Stanley Maintains Equal-Weight on Merck & Co, Raises Price Target to $102
📈 PositiveBenzinga•Dec 12, 2025, 05:21 PM
Merck's WINREVAIR Receives CHMP Recommendation For Expanded PAH Indication Covering WHO FC II–IV
📈 PositiveBenzinga•Dec 12, 2025, 01:46 PM
Formycon And Zydus Lifesciences Partner For Exclusive Licensing And Supply Of Checkpoint Inhibitor FYB206, Biosimilar Of Merck's Keytruda, In U.S. And Canada
📈 PositiveBenzinga•Dec 9, 2025, 12:20 PM
Merck Says Province Of Saskatchewan Adds CAPVAXIVE, 21-Valent Pneumococcal Conjugate Vaccine, To Publicly Funded Adult Immunization Program
📈 PositiveBenzinga•Dec 8, 2025, 12:21 PM
Merck, In A Statement, Says It Is Deeply Concerned By Advisory Committee on Immunization Practices Vote To Modify The Longstanding Hepatitis B Birth Dose Recommendation; Says The Decision Disregards Decades Of Safety And Effectiveness Data That Unequivocally Support Hepatitis B Birth Dose
📉 NegativeBenzinga•Dec 5, 2025, 05:14 PM
CDC Prevention Advisory Committee On Immunization Practices Voted To Abandon Universal Hepatitis B Vaccination For Newborns
📉 NegativeBenzinga•Dec 5, 2025, 03:43 PM•Also: ,
Scotiabank Maintains Sector Outperform on Merck & Co, Raises Price Target to $120
📈 PositiveBenzinga•Dec 4, 2025, 07:57 PM
Halozyme Therapeutics Granted Preliminary Injunction From German Court Against Merck's Keytruda
📈 PositiveBenzinga•Dec 4, 2025, 06:30 PM•Also:
Frequently Asked Questions about MRK
What is MRK's current stock price?
Merck & Co., Inc. (MRK) is currently trading at $101.09 per share. The stock has moved +0.40% today.
What is the analyst price target for MRK?
The average analyst price target for MRK is $116.29, based on 1 analyst.
What sector is Merck & Co., Inc. in?
Merck & Co., Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NYSE exchange.
What is MRK's market cap?
Merck & Co., Inc. has a market capitalization of $254.06 billion, making it a mega-cap company.
Does MRK pay dividends?
No, Merck & Co., Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABT
Abbott Laboratories
$125.42
Mkt Cap: $218.3B
AMGN
Amgen Inc.
$327.38
Mkt Cap: $176.3B
AZN
AstraZeneca PLC
$91.36
Mkt Cap: $283.3B
GILD
Gilead Sciences, Inc.
$124.29
Mkt Cap: $154.2B
GSK
GSK plc
$48.61
Mkt Cap: $98.8B
NVO
Novo Nordisk A/S
$48.09
Mkt Cap: $213.8B
NVS
Novartis AG
$136.06
Mkt Cap: $266.2B
PFE
Pfizer Inc.
$25.20
Mkt Cap: $143.3B
SNY
Sanofi
$48.18
Mkt Cap: $117.4B
TMO
Thermo Fisher Scientific Inc.
$567.83
Mkt Cap: $215.2B
Explore stocks similar to MRK for comparison